(−)‐Epigallocatechin Gallate Ameliorates Chronic Stress‐Induced Depression‐Like Behavior in Rats by Inhibiting the NF‐κB/Caspase‐1 Signaling Pathway and Reducing IL‐1β and IL‐18 Expression. Here, IL18 is linked to depressive symptom measurement.